Skip to main content
SpringerLink
Log in

Agomelatine

Innovative Pharmacological Approach in Depression

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Currently available antidepressant agents such as tricyclic antidepressants (TCAs) act primarily through monoaminergic systems in the brain, and have proved to be suboptimal for the management of major depressive disorder (MDD). Such agents are also active at non-target receptor sites, contributing to the development of often serious adverse events. Even the newer selective serotonin reuptake inhibitors (SSRIs), which also act through monoaminergic systems, have suboptimal antidepressant efficacy, and the adverse events that do occur often negatively influence adherence.

Although the pathophysiology of depression is not completely understood, it is increasingly recognized that monoamine deficiency/disruption is not the only pathway involved. Recognition that circadian rhythm desynchronization also plays a key role in mood disorders has led to the development of agomelatine, which is endowed with a novel mechanism of action distinct from that of currently available antidepressants. Agomelatine is an agonist of the melatonergic MT1 and MT2 receptors, as well as a 5-HT2C receptor antagonist. The antidepressant activity of agomelatine is proposed to stem from the synergy between these sets of receptors, which are key components of the circadian timing system.

Agomelatine has shown antidepressant-like activity in a number of animal models of depression, such as the learned helplessness model, the chronic mild stress model, the forced swim test and the chronic psychosocial stress test. Moreover, agomelatine has been found to restore normal circadian rhythms in animal models of a disrupted circadian system, and has proved beneficial in an animal model of delayed sleep phase syndrome. Likewise, it has been shown to improve disturbed sleep—wake rhythms in depressed patients. Moreover, current pharmacological and clinical data strongly support the use of agomelatine in the management of MDD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004(420): 21–7

  2. Sobocki P, Jonsson B, Angst J, et al. Cost of depression in Europe. J Ment Health Policy Econ 2006 Jun; 9(2): 87–98

    PubMed  Google Scholar 

  3. Baghai TC, Volz HP, Moller HJ. Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 2006; 7(4): 198–222

    Article  PubMed  Google Scholar 

  4. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000 Apr; 58(1): 19–36

    Article  PubMed  CAS  Google Scholar 

  5. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group.J Affect Disord 1990 Apr; 18(4): 289–99

    Article  Google Scholar 

  6. Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs 2001; 15(10): 765–76

    Article  PubMed  CAS  Google Scholar 

  7. Vestergaard P, Gram LF, Kragh-Sorensen P, et al. Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. Psychopharmacol Ser 1993; 10: 190–8

    CAS  Google Scholar 

  8. Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000 Nov; 15(6): 305–18

    Article  PubMed  CAS  Google Scholar 

  9. Judge R, Parry MG, Quail D, et al. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002 Sep; 17(5): 217–25

    Article  PubMed  CAS  Google Scholar 

  10. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 2000 Apr; 176: 363–8

    CAS  Google Scholar 

  11. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998 Jul 15; 44(2): 77–87

    Article  PubMed  CAS  Google Scholar 

  12. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006 Feb; 7(2): 137–51

    Article  PubMed  CAS  Google Scholar 

  13. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol 1996 Jun; 16(3 Suppl. 2): 1S–7S; discussion 75-95

    Article  PubMed  CAS  Google Scholar 

  14. Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004 Sep; 19(5): 271–80

    Article  PubMed  CAS  Google Scholar 

  15. Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol 2006; 21Suppl. 1: S11–15

    Article  PubMed  Google Scholar 

  16. Wehr TA, Wirz-Justice A. Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria 1982 Jan; 15(1): 31–9

    Article  PubMed  CAS  Google Scholar 

  17. Tylee A, Gastpar M, Lepine JP, et al. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 1999 May; 14(3): 139–51

    Article  CAS  Google Scholar 

  18. Lopes MC, Quera-Salva MA, Guilleminault C. Cyclic alternating pattern in the NREM sleep of patients within major depression disorder: baseline results and change overtime wirh a new antidepressant: agomelatine. Sleep Med 2005; 6Suppl. 2: 87–8

    Google Scholar 

  19. Quera-Salva MA, Vanier B, Chapotot F. Effect of agomelatine on the sleep EEG in patients with major depressive disorder. Eur Neuropsychopharmacol 2005; 15Suppl. 3: S435–6

    Google Scholar 

  20. Kupfer DJ. Sleep research in depressive illness: clinical implications — a tasting menu. Biol Psychiatry 1995 Sep 15; 38(6): 391–403

    Article  PubMed  CAS  Google Scholar 

  21. Souetre E, Salvati E, Belugou JL, et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 1989 Jun; 28(3): 263–78

    Article  PubMed  CAS  Google Scholar 

  22. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 2004; 65Suppl. 16: 27–32

    PubMed  Google Scholar 

  23. Moore RY. Organization and function of a central nervous system circadian oscillator: the suprachiasmatic hypothalamic nucleus. Fed Proc 1983 Aug; 42(11): 2783–9

    PubMed  CAS  Google Scholar 

  24. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry 1998; 155: 1119–21

    PubMed  CAS  Google Scholar 

  25. Audinot V, Mailliet F, Lahaye-Brasseur C, et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 2003 Jun; 367(6): 553–61

    Article  PubMed  CAS  Google Scholar 

  26. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003 Sep; 306(3): 954–64

    Article  PubMed  CAS  Google Scholar 

  27. Racagni G, Riva MA, Popoli M. The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol 2007 Oct; 22Suppl. 2: S9–14

    Article  PubMed  Google Scholar 

  28. Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006; 20(12): 981–92

    Article  PubMed  CAS  Google Scholar 

  29. Martinet L, Guardiola-Lemaitre B, Mocaer E. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav 1996 Aug; 54(4): 713–18

    Article  PubMed  CAS  Google Scholar 

  30. Masana MI, Benloucif S, Dubocovich ML. Circadian rhythm of mt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. J Pineal Res 2000 Apr; 28(3): 185–92

    Article  PubMed  CAS  Google Scholar 

  31. Papp M, Gruca P, Boyer PA, et al. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003 Apr; 28(4): 694–703

    Article  PubMed  CAS  Google Scholar 

  32. Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004 Mar; 29(2): 126–33

    PubMed  Google Scholar 

  33. Bertaina-Anglade V, la Rochelle CD, Boyer PA, et al. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 2006 Dec; 17(8): 703–13

    Article  PubMed  CAS  Google Scholar 

  34. Fuchs E, Simon M, Schmelting B. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int Clin Psychopharmacol 2006 Feb; 21Suppl. 1: S17–20

    Article  PubMed  Google Scholar 

  35. Armstrong SM, McNulty OM, Guardiola-Lemaitre B, et al. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 1993 Sep; 46(1): 45–9

    Article  PubMed  CAS  Google Scholar 

  36. Van Reeth O, Weibel L, Olivares E, et al. Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. Am J Physiol Regul Integr Comp Physiol 2001 May; 280(5): R1582–91

    Google Scholar 

  37. Weibel L, Turek FW, Mocaer E, et al. A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Res 2000 Oct 13; 880(1–2): 207–11

    Article  PubMed  CAS  Google Scholar 

  38. Redman JR, Francis AJ. Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J Biol Rhythms 1998 Feb; 13(1): 39–51

    Article  PubMed  CAS  Google Scholar 

  39. Shirayama M, Shirayama Y, Iida H, et al. The psychological aspects of patients with delayed sleep phase syndrome (DSPS). Sleep Med 2003 Sep; 4(5): 427–33

    Article  PubMed  Google Scholar 

  40. Cornbach S, Schmelting B, Fuchs E, et al. Comparison of agomelatine and melatonin for effects in chronically stressed tree shrews, an animal model of depression [Poster P.2.d.005]. In: 20th European College of Neuropsychopharmacology congress; 2007 Oct 13–17; Vienna, Austria. Eur Neuropsychopharmacol 2007; 17Suppl. 4: S364–5

    Article  Google Scholar 

  41. Barbiero V, Zappettini S, Mocaer E, et al. The novel antidepressant agomelatine reduces release of glutamate and related presynaptic mechanisms in rat hippocampus [Poster P.2.d.006]. In: 20th European College of Neuropsychopharmacology congress; 2007 Oct 13–17; Vienna, Austria. Eur Neuropsychopharmacol 2007; 17Suppl. 4: S365

    Article  Google Scholar 

  42. Bonanno G, Giambelli R, Raiteri L, et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005 Mar 30; 25(13): 3270–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Medical writing support was provided by Nila Bhana from Wolters Kluwer Health and was funded by Servier.

The author declares that he has performed consulting for Servier.

Author information

Authors and Affiliations

  1. Center of Neuropharmacology, Department of Pharmacological Sciences, University of Milano, Via Balzaretti 9, 20133, Milano, Italy

    Maurizio Popoli

Authors
  1. Maurizio Popoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurizio Popoli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Popoli, M. Agomelatine. CNS Drugs 23 (Suppl 2), 27–34 (2009). https://doi.org/10.2165/11318640-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11318640-000000000-00000

Keywords

Search

Navigation